Xenetic Biosciences Expands Collaboration with Scripps Research

Xenetic Biosciences, Inc. has announced an expansion of its collaboration with The Scripps Research Institute. The focus is on advancing the company's DNase-I and CAR T-cell therapy platform, particularly for lymphoma and leukemia. This collaboration aims to validate promising preclinical results observed so far.

Studies have demonstrated that the combination of systemic DNase I with CAR T-cell therapy notably reduces tumor burden and enhances survival in models of lymphoma and melanoma. This is achieved by degrading neutrophil extracellular traps (NETs), thus improving the efficacy of both CAR-T and endogenous T cells.

The program's expansion includes additional lymphoma and leukemia models. Xenetic aims to progress this technology into Phase 1 clinical trials, focusing on pancreatic carcinoma and other solid tumors.